

ESCCA 2022

WEDNESDAY 21 SEPTEMBER 2022

09.00-12.30 Training course 5: AML-MRD

Treatment intensity of acute myeloid leukemia (AML) patients is based on prognostic risk classification. One of the most important prognostic factors in AML is measurable residual disease (MRD) after intensive chemotherapy and therefore incorporated in clinical practice to select the appropriate consolidation treatment. Although molecular techniques are available, flow cytometry is currently the most commonly used. Recently the ELN AML MRD working party (ELN-DAVID) has published the latest technical insights (PMID: 34964040). Based on this, in this course we (Francesco Buccisano, Jacqueline Cloos and colleagues) will provide details on the different flow techniques and which facets of the measurements are key for accurate and good quality measurements, such as instrument settings, sample preparation, data analysis and reporting.

Level: Advanced

Organiser: Willemijn Hobo (Nijmegen, Amsterdam), Jacqueline Cloos (Amsterdam, NL)

09.00-09.10	Welcome	Francesco Buccisano (Rome, IT)
09.10-09.40	Clinical relevance of a standardized AML MRD assessment	Jacqueline Cloos (Amsterdam, NL)
09.40-10.10	FCM measurements - machine set-up and sample preparation	Angele Kelder (Amsterdam, NL)
10.10-10.40	FCM measurements - staining and measurement	Angele Kelder (Amsterdam, NL)
<i>10.30-11.00</i>	<i>Coffee break</i>	
11.15-11.45	FCM data analyses - LAIP definition	Willemijn Scholten (Amsterdam, NL)
11.45-12.15	FCM data analyses - live gating	Willemijn Scholten (Amsterdam, NL)
12.15-12.30	MRD results reporting	Angele Kelder (Amsterdam, NL)
<i>Lunch on your own</i>		
14.00	Start ESCCA Conference	

